Active surveillance
What is active surveillance?
Active surveillance is a way of monitoring localised (early) prostate cancer, rather than treating it straight away. You might hear it called active monitoring.
If you go on active surveillance, you’ll have regular tests to check on the cancer. The aim is to avoid unnecessary treatment unless these tests show that your cancer may be growing, or you decide you want treatment – so you’ll avoid or delay the side effects of treatment. If there are signs your cancer may be growing, you’ll be offered treatment that aims to cure your cancer.
It might seem strange not to have treatment, but localised prostate cancer often grows slowly – if at all – and may have a low risk of spreading. So it may never cause you any problems or affect how long you live. Many men on active surveillance will never need treatment.
Active surveillance isn’t the same as watchful waiting, which is a different way of monitoring prostate cancer. Read about the differences between active surveillance and watchful waiting.
Active surveillance fact sheet
This fact sheet is for anyone who wanted to know more about active surveillance.
Who can go on active surveillance?
Active surveillance is suitable for men with Cambridge Prognostic Group (CPG) 1 or 2 localised prostate cancer. This means your cancer hasn’t spread outside the prostate and has a low risk of spreading. It’s also sometimes suitable for men with CPG 3 localised prostate cancer who want to avoid or delay treatment.
If you have more aggressive prostate cancer that has a high risk of spreading (CPG 4 or 5) active surveillance won’t be recommended for you.
Your doctor will look at all your test results to see if active surveillance is an option for you. They will also make sure that:
you’re fit enough to have treatments such as surgery or radiotherapy if your cancer starts to grow
you know about the advantages and disadvantages of being on active surveillance
you’ve discussed other treatment options with your doctor or nurse and you’re happy to go on active surveillance.
Talk to your doctor or nurse if you have any questions about your test results or treatment options. You can also get in touch with our Specialist Nurses.
What are the advantages and disadvantages?
Deciding whether or not to go on active surveillance is a personal choice. What may be important to one person might not be to someone else. If you’re offered active surveillance, speak to your doctor or nurse before deciding whether to go on it – they can help you decide whether it’s right for you. You may find it helpful to use our list of questions to ask your doctor or nurse.
Advantages
As you won’t have treatment while you’re on active surveillance, you’ll avoid the side effects of treatment.
Active surveillance won’t affect your everyday life as much as treatment might.
If tests show that your cancer might be growing, there are treatments available that aim to cure your cancer.
Disadvantages
You might need to have more prostate biopsies which can cause side effects, and which some men find uncomfortable or painful.
Your general health could change, which might make some treatments unsuitable for you if you did need them.
Some men may worry about not having treatment, and about their cancer growing – but you can change your mind and have treatment instead if this is a problem.
Your cancer might grow more quickly than expected and become harder to treat – but this is very uncommon.
The idea of being on active surveillance was attractive, because I didn't have to worry about side effects as I wasn't having any treatment.
What does active surveillance involve?
You’ll have regular tests to monitor your cancer. The tests aim to find any changes that suggest the cancer is growing. Depending on your hospital, you may have:
This is a blood test that measures the amount of prostate specific antigen (PSA) in your blood. PSA is a protein produced by normal cells in the prostate, and by prostate cancer cells.
You will have had a PSA test to help diagnose your cancer. It’s also a useful test for monitoring prostate cancer. It’s normal for your PSA level to go up a little as you get older and your prostate gets bigger. And other things can cause it to rise, like an infection, recent ejaculation, anal or prostate stimulation, vigorous exercise, such as running and cycling, and some medicines or supplements. You should try to avoid sexual activity and vigorous exercise in the 48 hours before a PSA test. But if your PSA level rises faster than expected, this could be a sign that your cancer is growing.
If your doctor is concerned by any of these test results, they might recommend an MRI scan or a prostate biopsy to check if the cancer is growing.
Read more about the PSA blood test.
Booking your PSA blood test
Depending on your hospital, you may have your PSA tests at your local hospital, or you may need to book these tests yourself at your GP surgery. This varies from hospital to hospital.
Your doctor or nurse may send you a letter saying how often you should have PSA tests. But you might not get reminders, so check with your doctor so you know how often you need one. Give yourself plenty of time to book them, as hospitals and GP surgeries can be very busy and you may not be able to get an appointment straight away.
You should have an MRI scan when you first go on active surveillance to make sure your cancer hasn’t spread outside the prostate. You may then have regular MRI scans, although this will depend on your hospital. Your doctor may also suggest having an MRI scan if your PSA test or DRE results suggest your cancer might be growing. The scan can help your doctor decide if you need a biopsy.
Read more about MRI scans.
This is where the doctor feels your prostate through the wall of the back passage (rectum). A normal prostate should feel soft and smooth. Your doctor will feel your prostate for any changes, such as hard or lumpy areas, that could suggest the cancer is growing.
Read more about having a DRE.
Once you start active surveillance, you may only have another biopsy if other tests suggest your cancer is growing. Your PSA level might rise a little, even if your cancer isn’t growing. Your doctor will decide if it has risen enough for you to need a biopsy.
If you do have a biopsy that shows your cancer has grown, then your doctor may recommend you have treatment. This treatment will usually aim to get rid of the cancer.
Read more about prostate biopsies.
How often will I have tests?
The tests you have, and how often you have them, will depend on your hospital. The following is an example, but your doctor will tell you how often you will have tests.
First year of active surveillance
A PSA test every three to four months
A DRE after 12 months
An MRI scan after 12 to 18 months.
Second year onwards
A PSA test every six months
A DRE every 12 months.
Some hospitals may offer tests more or less often depending on the risk of your prostate cancer growing and spreading. You might hear this called risk stratified active surveillance. Speak to your doctor or medical team if you have any questions or concerns.
Life on active surveillance diary
You may find it helpful to use our Life on active surveillance diary to keep track of your appointment details and also record your test results.
When would I stop active surveillance?
If the results of the tests show your cancer is growing or has become more aggressive, you’ll be offered treatment that aims to get rid of the cancer – for example, surgery or radiotherapy.
You can decide to have treatment at any time, no matter how long you have been on active surveillance. Living with cancer and not having treatment can be difficult, and you may experience feelings of stress, worry and anxiety. Some men decide they want to have treatment even though there are no signs of any changes. If you decide you do want treatment, speak to your doctor or nurse.
Is active surveillance safe?
Research shows active surveillance is a safe way for men with low risk prostate cancer to avoid or delay unnecessary treatment. And you have the same chances of living for 15 years or more as you would if you chose to have treatment with surgery or radiotherapy.
Picking up changes to your cancer
There’s a chance that your cancer could grow. But the risk of it growing without being picked up is very low. And the tests used to monitor your cancer should find any changes early enough to treat it.
There is a very small chance that the cancer will spread outside your prostate before being picked up, and treatment might not be able to get rid of it completely.
This can happen if:
the tests used in active surveillance miss changes in your cancer, or
the tests used to diagnose your prostate cancer didn’t find some areas of faster-growing cancer.
But this is very uncommon. And you’ll have regular tests to check on the cancer and make sure it isn’t growing. Talk to your doctor or nurse if you’re worried about the risk of your cancer growing.
Concerns about not having treatment
Many men with low risk localised prostate cancer choose to go on active surveillance. But active surveillance isn’t for everyone. You might find it difficult not having treatment for prostate cancer, and worry that your cancer will change or spread. Some men on active surveillance decide to have treatment even though there are no signs of any changes in their cancer.
If at any time you decide that you want treatment, talk to your doctor or nurse. You don’t have to stay on active surveillance if you don’t want to.
Changes to your health
There’s a chance that your general health could change. This could make some treatments unsuitable for you if the cancer did grow. For example, if you were to get heart problems, you might not be able to have surgery to remove your prostate, as an operation might not be safe for you.
You can lower your risk of many health problems by eating healthily and doing regular exercise. Read more about diet and physical activity.
You can also lower your risk of many health problems by giving up smoking. Some research also suggests that smoking makes prostate cancer more likely to grow and spread to other parts of the body. And the more you smoke, the greater the risk. If you smoke, talk to your doctor or nurse for support to help you stop, or visit the NHS Smokefree website.
Are there any side effects?
No, as you won’t have treatment while you’re on active surveillance, you won't get any of the side effects of treatment.
If you do notice changes to the way you urinate, speak to your doctor or nurse. These changes are more likely to be a sign of an enlarged prostate, or another health problem. But it’s still a good idea to get it checked out.
You might need to have prostate biopsies while you’re on active surveillance though, and these can cause some short-term side effects. But many hospitals now do MRI scans instead of regular prostate biopsies.
Questions to ask your doctor or nurse
A list of any questions you may want to take to your next appointment:
Am I going on active surveillance or watchful waiting?
Where will my appointments be?
How often will I have my PSA level checked?
Who will be in charge of booking my PSA tests?
Who will check my PSA level and give me the results?
How often will I see my doctor or nurse?
Will I have other regular tests or scans? If so, which ones and how often?
What test results would lead you to recommend treatment? Are there any specific results that mean I should have further tests?
What treatments could I have if my cancer grows?
What symptoms should I look out for and report?
What do I do if I change my mind and want to have treatment?
What can I do to improve my general health?
References and reviewers
Updated: May 2026 | Due for Review: May 2027
Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. The Lancet. 2017 Jan. doi:10.1016/S0140-6736(16)32401-1
Andersen MF, Midtgaard J, Bjerre ED. Do Patients with Prostate Cancer Benefit from Exercise Interventions? A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2022 Jan;19(2):2. doi:10.3390/ijerph19020972
Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S, et al. Complications After Systematic, Random, and Image-guided Prostate Biopsy. Eur Urol. 2017 Mar 1;71(3):353–65. doi:10.1016/j.eururo.2016.08.004
Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol. 2013 Apr;63(4):597–603. doi:10.1016/j.eururo.2012.11.005 PubMed PMID: 23159452.
Cornford et al. EAU Guidelines on Prostate Cancer - Uroweb [Internet]. 2026 [cited 2026 Mar 23]. Available from: https://uroweb.org/guidelines/prostate-cancer
Cornu JN, Gacci M, Hashim H, Herrmann TRW, Malde S, Netsch C, et al. EAU Guidelines on Non Neurogenic Male LUTS [Internet]. European Association of Urology; 2025 [cited 2025 Jul 8]. Available from: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-Neurogenic-Male-LUTS-2025.pdf
Davis KM, Kelly SP, Luta G, Tomko C, Miller AB, Taylor KL. The Association of Long-term Treatment-related Side Effects With Cancer-specific and General Quality of Life Among Prostate Cancer Survivors. Urology. 2014 Aug;84(2):300–6. doi:10.1016/j.urology.2014.04.036 PubMed PMID: 24975711; PubMed Central PMCID: PMC5862141.
Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2016 Sep 14. doi:10.1056/NEJMoa1606221
Donnelly DW, Donnelly C, Kearney T, Weller D, Sharp L, Downing A, et al. Urinary, bowel and sexual health in older men from Northern Ireland. BJU Int. 2018 Nov;122(5):845–57. doi:10.1111/bju.14182
Dovey Z, Horowitz A, Waingankar N. The influence of lifestyle changes (diet, exercise and stress reduction) on prostate cancer tumour biology and patient outcomes: A systematic review. BJUI Compass. 2023;4(4):385–416. doi:10.1002/bco2.237
Gabb H, Gnanapragasam VJ. Value of a confirmatory re‐biopsy as part of a modern risk stratified cancer surveillance programme for early prostate cancer. BJUI Compass. 2024 Jun 1;5(7):662–4. doi:10.1002/bco2.406 PubMed PMID: 39022658; PubMed Central PMCID: PMC11250161.
Gnanapragasam VJ, Keates A, Lophatananon A, Thankapannair V. The 5-year results of the Stratified Cancer Active Surveillance programme for men with prostate cancer. BJU Int. 2025;135(5):851–9. doi:10.1111/bju.16666
GOV.UK [Internet]. [cited 2022 Jan 5]. Advising well men about the PSA test for prostate cancer: information for GPs. Available from: https://www.gov.uk/government/publications/prostate-specific-antigen-testing-explanation-and-implementation/advising-well-men-about-the-psa-test-for-prostate-cancer-information-for-gps
Hamblen AJ, Bray JW, Hingorani M, Saxton JM. Physical activity and dietary considerations for prostate cancer patients: future research directions. Proc Nutr Soc. 2023 Sep;82(3):298–304. doi:10.1017/S0029665123000046
Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016 Sep 14. doi:10.1056/NEJMoa1606220
Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2023 Apr 27;388(17):1547–58. doi:10.1056/NEJMoa2214122
Husson O, Mols F, Poll-Franse LV van de. The relation between information provision and health-related quality of life, anxiety and depression among cancer survivors: a systematic review. Ann Oncol. 2010 Sep 24;mdq413. doi:10.1093/annonc/mdq413 PubMed PMID: 20870912.
Johnson EE, Mamoulakis C, Stoniute A, Omar MI, Sinha S. Conservative interventions for managing urinary incontinence after prostate surgery. Cochrane Database Syst Rev. 2023;2023(4). doi:10.1002/14651858.cd014799.pub2
Kato T, Sugimoto M. Quality of life in active surveillance for early prostate cancer. Int J Urol. 2020;27(4):296–306. doi:10.1111/iju.14202
Kinsella N, Stattin P, Cahill D, Brown C, Bill-Axelson A, Bratt O, et al. Factors Influencing Men’s Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review. Eur Urol. 2018 Mar. doi:10.1016/j.eururo.2018.02.026
Lardas M, Liew M, van den Bergh RC, De Santis M, Bellmunt J, Van den Broeck T, et al. Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. Eur Urol. 2017 Dec;72(6):869–85. doi:10.1016/j.eururo.2017.06.035
Maggi M, Cowan JE, Fasulo V, Washington SL, Lonergan PE, Sciarra A, et al. The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer. J Urol. 2020 Dec;204(6):1222–8. doi:10.1097/JU.0000000000001313
National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management. 2021.
Nguyen DD, Berlin A, Matthew AG, Perlis N, Elterman DS. Sexual function and rehabilitation after radiation therapy for prostate cancer: a review. Int J Impot Res. 2021 May;33(4):410–7. doi:10.1038/s41443-020-00389-1
Rajwa P, Sprenkle PC, Leapman MS. When and How Should Active Surveillance for Prostate Cancer End? Eur Urol Focus. 2021 Mar;7(2):297–300. doi:10.1016/j.euf.2020.01.001 PubMed PMID: 32019719; PubMed Central PMCID: PMC7394715.
Razdan S, Pandav K, Altschuler J, Moody K, Martin L, Patel HD, et al. Impact of exercise on continence in prostate cancer patients post robotic assisted radical prostatectomy: a systematic review. Am J Clin Exp Urol. 2023 Aug 15;11(4):320–7. PubMed PMID: 37645610; PubMed Central PMCID: PMC10461030.
Ruane-McAteer E, Porter S, O’sullivan JM, Santin O, Prue G. Active surveillance for favorable-risk prostate cancer: Is there a greater psychological impact than previously thought? A systematic, mixed studies literature review. Psychooncology. 2017;26(10):1411–21.
Simpkin AJ, Tilling K, Martin RM, Lane JA, Hamdy FC, Holmberg L, et al. Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer. Eur Urol. 2015 Jun;67(6):993–1005. doi:10.1016/j.eururo.2015.01.004
Træen B, Hald GM, Graham CA, Enzlin P, Janssen E, Kvalem IL, et al. Sexuality in Older Adults (65+)—An Overview of the Literature, Part 1: Sexual Function and its Difficulties. Int J Sex Health. 2017 Jan 2;29(1):1–10. doi:10.1080/19317611.2016.1224286
Wang L, Wu L, Qian C, Ju Y, Liu T, Chen Y, et al. The Beneficial Effect of a Healthy Dietary Pattern on Androgen Deprivation Therapy-Related Metabolic Abnormalities in Patients with Prostate Cancer: A Meta-Analysis Based on Randomized Controlled Trials and Systematic Review. Metabolites. 2022 Oct 13;12(10):969. doi:10.3390/metabo12100969
Wedlake LJ. Nutritional strategies to prevent gastrointestinal toxicity during pelvic radiotherapy. Proc Nutr Soc. 2018 Nov;77(4):357–68. doi:10.1017/s0029665118000101
Wilt TJ, Jones KM, Barry MJ, Andriole GL, Culkin D, Wheeler T, et al. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med. 2017 Jul 13;377(2):132–42. doi:10.1056/NEJMoa1615869
Yuan F, Wang Y, Xiao X, Zhang X, Jing M, Kamecki H, et al. A systematic review evaluating the effectiveness of exercise training on physical condition in prostate cancer patients undergoing androgen deprivation therapy. Transl Androl Urol. 2023 Aug 31;12(8):8. doi:10.21037/tau-23-272
Our Health Information Team
Our Specialist Nurses.
You may also be interested in...
Watchful waiting
Localised prostate cancer
Active surveillance fact sheet
